Use of c3-c10 17alfa-esters of 9,11-dehydrocortexolone as anti-gonadotrophic agents
AssigneeCosmo Bio-Technologies Srl
InventorsLuigi Moro, Mauro Ajani, Giuseppe Celasco
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of C3-C10 17α-esters of 9,11-dehydrocortexolone as agents for inhibiting gonadotrophin secretion. The present invention therefore relates to the use of C3-C10 17 α-esters of 9,11-dehydrocortexolone for the preparation of a medicine for the treatment of disorders associated with the secretion of gonadotrophin and with the corresponding pharmaceutical compounds. The present invention relates specifically to the use of 9,11-dehydrocortexolone 17α-butyrate.
Claims31
1-19. (canceled)
A method for treating prostate tumour, polycystic ovary and/or gonadotropin-dependent precocious puberty, which comprises administering a C3-C10 17α-ester of 9,11-dehydrocortexolone having the formula
- wherein R1 is hydrogen and R2 is C3-C10 acyl.
A method for controlling aberrant sexual behaviour, male contraception, hot flushes in women and/or ovarian stimulation in assisted fertilization methods, which comprises administering a C3-C10 17α-ester of 9,11-dehydrocortexolone having the formula wherein R1 is hydrogen and R2 is C3-C10 acyl.
Pharmaceutical compositions containing as their active principle C3-C10 17α-esters of 9,11-dehydrocortexolone, having the formula
- in which R1 is hydrogen and R2 is C3-C10 acyl, in association with pharmacologically acceptable excipients.
Dependencies are inferred from the claim text.